RSPO1 and mucositis: Therefore, the methodologies here described for production and purification of a biologically active recombinant human RSPO1 to be used in Cell Therapy open new avenues for further optimization of its bioprocess and may contribute, in the future, to treatment of medical conditions, such as chemotherapy [33] or radiation-induced mucositis [34], inflammatory bowel diseases [31, 35], diabetes [36, 37], joint diseases [38] and even cancer [38, 60], as previously suggested by several authors based on animal models.